Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 163

1.

Plasma YKL-40 in Inuit and Danes.

Nøjgaard C, Johansen JS, Bjerregaard P, Bojesen SE, Becker U.

Alcohol Alcohol. 2014 Oct 20. pii: agu072. [Epub ahead of print]

PMID:
25332349
[PubMed - as supplied by publisher]
2.

Tissue MicroRNAs as Predictors of Outcome in Patients with Metastatic Colorectal Cancer Treated with First Line Capecitabine and Oxaliplatin with or without Bevacizumab.

Boisen MK, Dehlendorff C, Linnemann D, Nielsen BS, Larsen JS, Osterlind K, Nielsen SE, Tarpgaard LS, Qvortrup C, Pfeiffer P, Holländer NH, Keldsen N, Hansen TF, Jensen BB, Høgdall EV, Jensen BV, Johansen JS.

PLoS One. 2014 Oct 15;9(10):e109430. doi: 10.1371/journal.pone.0109430. eCollection 2014.

PMID:
25329796
[PubMed - in process]
Free Article
3.

YKL-40 and Alcoholic Liver and Pancreas Damage and Disease in 86 258 Individuals from the General Population: Cohort and Mendelian Randomization Studies.

Kjaergaard AD, Bojesen SE, Nordestgaard BG, Johansen JS.

Clin Chem. 2014 Sep 15. pii: clinchem.2014.229096. [Epub ahead of print]

PMID:
25225167
[PubMed - as supplied by publisher]
4.

FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study.

Geva R, Vecchione L, Kalogeras KT, Vittrup Jensen B, Lenz HJ, Yoshino T, Paez D, Montagut C, Souglakos J, Cappuzzo F, Cervantes A, Frattini M, Fountzilas G, Johansen JS, Høgdall EV, Zhang W, Yang D, Yamazaki K, Nishina T, Papamichael D, Vincenzi B, Macarulla T, Loupakis F, De Schutter J, Spindler KL, Pfeiffer P, Ciardiello F, Piessevaux H, Tejpar S.

Gut. 2014 Jul 10. pii: gutjnl-2014-307234. doi: 10.1136/gutjnl-2014-307234. [Epub ahead of print]

PMID:
25011934
[PubMed - as supplied by publisher]
5.

miR-345 in metastatic colorectal cancer: a non-invasive biomarker for clinical outcome in non-KRAS mutant patients treated with 3rd line cetuximab and irinotecan.

Schou JV, Rossi S, Jensen BV, Nielsen DL, Pfeiffer P, Høgdall E, Yilmaz M, Tejpar S, Delorenzi M, Kruhøffer M, Johansen JS.

PLoS One. 2014 Jun 18;9(6):e99886. doi: 10.1371/journal.pone.0099886. eCollection 2014.

PMID:
24940606
[PubMed - in process]
Free PMC Article
6.

Antibody directed against human YKL-40 increases tumor volume in a human melanoma xenograft model in scid mice.

Salamon J, Hoffmann T, Elies E, Peldschus K, Johansen JS, Lüers G, Schumacher U, Wicklein D.

PLoS One. 2014 Apr 21;9(4):e95822. doi: 10.1371/journal.pone.0095822. eCollection 2014.

PMID:
24752554
[PubMed - in process]
Free PMC Article
7.

Brain barriers and a subpopulation of astroglial progenitors of developing human forebrain are immunostained for the glycoprotein YKL-40.

Bjørnbak C, Brøchner CB, Larsen LA, Johansen JS, Møllgård K.

J Histochem Cytochem. 2014 May;62(5):369-88. doi: 10.1369/0022155414528514. Epub 2014 Mar 4.

PMID:
24595665
[PubMed - indexed for MEDLINE]
8.

Plasma YKL-40 in patients with metastatic colorectal cancer treated with first line oxaliplatin-based regimen with or without cetuximab: RESULTS from the NORDIC VII Study.

Tarpgaard LS, Guren TK, Glimelius B, Christensen IJ, Pfeiffer P, Kure EH, Sorbye H, Ikdahl T, Yilmaz M, Johansen JS, Tveit KM.

PLoS One. 2014 Feb 3;9(2):e87746. doi: 10.1371/journal.pone.0087746. eCollection 2014. Erratum in: PLoS One. 2014;9(5):e98836.

PMID:
24498368
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

MicroRNA biomarkers in whole blood for detection of pancreatic cancer.

Schultz NA, Dehlendorff C, Jensen BV, Bjerregaard JK, Nielsen KR, Bojesen SE, Calatayud D, Nielsen SE, Yilmaz M, Holländer NH, Andersen KK, Johansen JS.

JAMA. 2014 Jan 22-29;311(4):392-404. doi: 10.1001/jama.2013.284664.

PMID:
24449318
[PubMed - indexed for MEDLINE]
10.

A treat-to-target strategy with methotrexate and intra-articular triamcinolone with or without adalimumab effectively reduces MRI synovitis, osteitis and tenosynovitis and halts structural damage progression in early rheumatoid arthritis: results from the OPERA randomised controlled trial.

Axelsen MB, Eshed I, Hørslev-Petersen K, Stengaard-Pedersen K, Hetland ML, Møller J, Junker P, Pødenphant J, Schlemmer A, Ellingsen T, Ahlquist P, Lindegaard H, Linauskas A, Dam MY, Hansen I, Horn HC, Ammitzbøll CG, Jørgensen A, Krintel SB, Raun J, Krogh NS, Johansen JS, Ostergaard M; OPERA study group.

Ann Rheum Dis. 2014 Jan 16. doi: 10.1136/annrheumdis-2013-204537. [Epub ahead of print]

PMID:
24412895
[PubMed - as supplied by publisher]
11.

Plasma YKL-40 and all-cause mortality in patients with chronic obstructive pulmonary disease.

Holmgaard DB, Mygind LH, Titlestad IL, Madsen H, Pedersen SS, Johansen JS, Pedersen C.

BMC Pulm Med. 2013 Dec 30;13:77. doi: 10.1186/1471-2466-13-77.

PMID:
24373580
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Genetic variants in CHI3L1 influencing YKL-40 levels: resequencing 900 individuals and genotyping 9000 individuals from the general population.

Kjaergaard AD, Johansen JS, Nordestgaard BG, Bojesen SE.

J Med Genet. 2013 Dec;50(12):831-7. doi: 10.1136/jmedgenet-2013-101908. Epub 2013 Sep 23.

PMID:
24062521
[PubMed - indexed for MEDLINE]
13.

Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer.

Boisen MK, Johansen JS, Dehlendorff C, Larsen JS, Osterlind K, Hansen J, Nielsen SE, Pfeiffer P, Tarpgaard LS, Holländer NH, Keldsen N, Hansen TF, Jensen BB, Jensen BV.

Ann Oncol. 2013 Oct;24(10):2554-9. doi: 10.1093/annonc/mdt253. Epub 2013 Jul 17.

PMID:
23864097
[PubMed - indexed for MEDLINE]
Free Article
14.

Diagnostic and Prognostic Impact of Circulating YKL-40, IL-6, and CA 19.9 in Patients with Pancreatic Cancer.

Schultz NA, Christensen IJ, Werner J, Giese N, Jensen BV, Larsen O, Bjerregaard JK, Pfeiffer P, Calatayud D, Nielsen SE, Yilmaz MK, Holländer NH, Wøjdemann M, Bojesen SE, Nielsen KR, Johansen JS.

PLoS One. 2013 Jun 26;8(6):e67059. Print 2013.

PMID:
23840582
[PubMed - as supplied by publisher]
Free PMC Article
15.

Plasma YKL-40 and CHI3L1 in systemic inflammation and sepsis-experience from two prospective cohorts.

Kornblit B, Hellemann D, Munthe-Fog L, Bonde J, Strøm JJ, Madsen HO, Johansen JS, Garred P.

Immunobiology. 2013 Oct;218(10):1227-34. doi: 10.1016/j.imbio.2013.04.010. Epub 2013 Apr 24.

PMID:
23706599
[PubMed - indexed for MEDLINE]
16.

Protein conformational change delayed by steric hindrance from an N-linked glycan.

Bager R, Johansen JS, Jensen JK, Stensballe A, Jendroszek A, Buxbom L, Sørensen HP, Andreasen PA.

J Mol Biol. 2013 Aug 23;425(16):2867-77. doi: 10.1016/j.jmb.2013.05.007. Epub 2013 May 20.

PMID:
23702291
[PubMed - indexed for MEDLINE]
17.

The frequency of anti-infliximab antibodies in patients with rheumatoid arthritis treated in routine care and the associations with adverse drug reactions and treatment failure.

Krintel SB, Grunert VP, Hetland ML, Johansen JS, Rothfuss M, Palermo G, Essioux L, Klause U.

Rheumatology (Oxford). 2013 Jul;52(7):1245-53. doi: 10.1093/rheumatology/ket017. Epub 2013 Mar 4.

PMID:
23459699
[PubMed - indexed for MEDLINE]
18.

Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial.

Hørslev-Petersen K, Hetland ML, Junker P, Pødenphant J, Ellingsen T, Ahlquist P, Lindegaard H, Linauskas A, Schlemmer A, Dam MY, Hansen I, Horn HC, Ammitzbøll CG, Jørgensen A, Krintel SB, Raun J, Johansen JS, Østergaard M, Stengaard-Pedersen K; OPERA Study-Group.

Ann Rheum Dis. 2014 Apr;73(4):654-61. doi: 10.1136/annrheumdis-2012-202735. Epub 2013 Feb 23.

PMID:
23434570
[PubMed - indexed for MEDLINE]
19.

Serum YKL-40 predicts long-term mortality in patients with stable coronary disease: a prognostic study within the CLARICOR trial.

Harutyunyan M, Gøtze JP, Winkel P, Johansen JS, Hansen JF, Jensen GB, Hilden J, Kjøller E, Kolmos HJ, Gluud C, Kastrup J.

Immunobiology. 2013 Jul;218(7):945-51. doi: 10.1016/j.imbio.2012.10.015. Epub 2012 Nov 7.

PMID:
23294528
[PubMed - indexed for MEDLINE]
20.

The inflammatory biomarker YKL-40 at admission is a strong predictor of overall mortality.

Mygind ND, Iversen K, Køber L, Goetze JP, Nielsen H, Boesgaard S, Bay M, Johansen JS, Nielsen OW, Kirk V, Kastrup J.

J Intern Med. 2013 Feb;273(2):205-16. doi: 10.1111/joim.12006. Epub 2012 Dec 31.

PMID:
23140269
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk